- Home
- CPT vs ASND Comparison
CPT vs ASND Comparison
Compare CPT & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPT
- ASND
- Stock Information
- Founded
- CPT 1993
- ASND 2006
- Country
- CPT United States
- ASND Denmark
- Employees
- CPT N/A
- ASND N/A
- Industry
- CPT Real Estate Investment Trusts
- ASND Biotechnology: Pharmaceutical Preparations
- Sector
- CPT Real Estate
- ASND Health Care
- Exchange
- CPT Nasdaq
- ASND Nasdaq
- Market Cap
- CPT 11.6B
- ASND 10.6B
- IPO Year
- CPT 1993
- ASND 2015
- Fundamental
- Price
- CPT $109.42
- ASND $194.30
- Analyst Decision
- CPT Buy
- ASND Strong Buy
- Analyst Count
- CPT 18
- ASND 16
- Target Price
- CPT $125.72
- ASND $239.88
- AVG Volume (30 Days)
- CPT 1.0M
- ASND 566.6K
- Earning Date
- CPT 07-31-2025
- ASND 08-07-2025
- Dividend Yield
- CPT 3.89%
- ASND N/A
- EPS Growth
- CPT N/A
- ASND N/A
- EPS
- CPT 1.43
- ASND N/A
- Revenue
- CPT $1,570,124,000.00
- ASND $576,332,355.00
- Revenue This Year
- CPT $2.42
- ASND $101.37
- Revenue Next Year
- CPT $3.20
- ASND $76.17
- P/E Ratio
- CPT $76.43
- ASND N/A
- Revenue Growth
- CPT 0.75
- ASND 54.50
- 52 Week Low
- CPT $102.35
- ASND $111.09
- 52 Week High
- CPT $127.69
- ASND $199.99
- Technical
- Relative Strength Index (RSI)
- CPT 51.12
- ASND 62.30
- Support Level
- CPT $107.46
- ASND $191.44
- Resistance Level
- CPT $109.45
- ASND $197.35
- Average True Range (ATR)
- CPT 1.72
- ASND 7.99
- MACD
- CPT 0.52
- ASND 0.18
- Stochastic Oscillator
- CPT 91.16
- ASND 77.06
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.